Research Article
Clinical Implications of Bifurcation Angles in Left Main Bifurcation Intervention Using a Two-Stent Technique
Table 1
Baseline clinical, angiographic, and procedural characteristics of the study population.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Values are mean ± SD, median (interquartile ranges, 25th–75th), or n (%) (per-patient analysis). Chronic kidney disease defined as a glomerular filtration rate (GFR) < 60 ml/min/1.73 m2. BP-BES, biodegradable polymer biolimus-eluting stent; CABG, coronary artery bypass grafting; CAD, coronary artery disease; DES, drug-eluting stent; EES, everolimus-eluting stent; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main; LV, left ventricle; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent; STEMI, ST-segment elevation myocardial infarction; ZES, zotarolimus-eluting stent. |